Loading...
XNAS
CDNA
Market cap3.22bUSD
Oct 08, Last price  
62.21USD
1D
-1.32%
1Q
118.19%
Jan 2017
2,203.89%
IPO
522.05%
Name

CareDx Inc

Chart & performance

D1W1MN
XNAS:CDNA chart
P/E
—
P/S
8.47
EPS
—
Div yield, %
—
Shrs. gr., 5y
2.77%
Rev. gr., 5y
14.59%
Revenues
380m
+13.79%
20,451,00022,098,00027,306,00028,144,00040,631,00048,324,00076,569,000127,068,000192,194,000296,397,000321,793,000280,324,000333,785,000379,805,000
Net income
-21m
L
-5,059,000-3,542,000781,000-13,707,000-39,469,000-55,469,000-46,756,000-21,968,000-18,714,000-30,662,000-76,613,000-190,284,00052,549,000-21,354,000
CFO
42m
+10.47%
-1,776,000-546,000-3,350,000-9,752,000-16,523,000-14,307,000-4,007,000-2,769,00033,431,000-19,294,000-25,239,000-18,388,00038,048,00042,032,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.

Key people

Independent Chairman of the Board · since 2021
John Hanna
President, Chief Executive Officer, Director · since 2024
Keith Kennedy
Chief Operating Officer · since 2024
Jennifer Foley
Chief Product Officer · since 2025
Jessica Meng
Chief Commercial Officer · since 2024
Jeffrey Novack
General Counsel, Secretary · since 2024
Suresh Gunasekaran
Director · since 2025
Independent Director · since 2014
Independent Director · since 2003
Independent Director · since 2019
William Hagstrom
Independent Director · since 2015
Peter Maag
Independent Director · since 2024
R. Bryan Riggsbee
Independent Director · since 2024
Arthur Torres
Independent Director · since 2021
Hannah Valantine
Independent Director · since 2021
IPO date
Jul 17, 2014
Employees
727
Domiciled in
US
Incorporated in
US
Legal address
C/O The Corporation Trust Company
Corporation Trust Center
1209 Orange Street
Wilmington, DE 19801
US
Headquarters
3260 Bayshore Boulevard
Brisbane, CA 94005
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT